Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 37Lung Neoplasms 27Triple Negative Breast Neoplasms 25Ovarian Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Fallopian Tube Neoplasms 16Small Cell Lung Carcinoma 15Neoplasm Metastasis 14Endometrial Neoplasms 13Esophageal Neoplasms 11Neoplasms 10Prostatic Neoplasms 9Colorectal Neoplasms 9Head and Neck Neoplasms 8Carcinoma 8Urinary Bladder Neoplasms 7Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Oropharyngeal Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Laryngeal Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Squamous Cell 5Stomach Neoplasms 4Mouth Neoplasms 4Melanoma 4Carcinoma, Ovarian Epithelial 4Urothelial Cancer 3

Interventions

Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hormone Refractory Prostate Cancer × Carboplatin × Clear all
NCT02955082 2026-02-04

BARCODE2

Institute of Cancer Research, United Kingdom

Phase 2 Active not recruiting
305 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡